Similar Papers

Paper Title
Journal
Date
Author
Subgroup Analysis of Japanese Patients in a Phase I/III Study of Atezolizumab in ES-SCLC (IMpower133)
Yosuke Kawashima ... Shinji Atagi
Annals of Oncology | VOL. 30
Yosuke Kawashima, et. al.Yosuke Kawashima ... Shinji Atagi
01 Oct 2019
Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).
Hiroji Iwata ... Yoshinori Ito
Japanese Journal of Clinical Oncology | VOL. 49
Hiroji Iwata, et. al.Hiroji Iwata ... Yoshinori Ito
15 Oct 2019
Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).
Hiroji Iwata ... Kenji Tamura
Japanese journal of clinical oncology | VOL. 50
Hiroji Iwata, et. al.Hiroji Iwata ... Kenji Tamura
17 Jan 2020
Patterns of Relapse and Implications for Post-Nephrectomy Surveillance for Patients with High-Risk Non-Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial
Vivek Narayan ... Robert S Dipaola
Journal of Urology | VOL. 201
Vivek Narayan, et. al.Vivek Narayan ... Robert S Dipaola
18 Aug 2018
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
A Perspective on the MARS2 Trial
Eric Lim ... Harvey Pass
Journal of Thoracic Oncology | VOL. -
Eric Lim, et. al.Eric Lim ... Harvey Pass
01 Jan 2025
Meeting Announcements
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03
Afshin Dowlati ... Saiama N Waqar
Journal of Thoracic Oncology | VOL. -
Afshin Dowlati, et. al.Afshin Dowlati ... Saiama N Waqar
01 Jan 2025
Editorial Board
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.